reported that imeglimin improved hepatic steatosis in high-fat, high-sucrose diet-fed mice by enhancing glucagon secretion and thereby suppressing lipogenesis and promoting fatty acid oxidation (21). The gene discussed is GCG; the disease is fatty liver disease.